Boletín de AInvest
Titulares diarios de acciones y criptomonedas, gratis en tu bandeja de entrada
On April 14, 2025,
(ABT) saw a trading volume of $894 million, ranking 75th in the day's stock market activity. The company's stock price increased by 0.85%, marking the second consecutive day of gains, with a total increase of 2.78% over the past two days.Stifel Nicolaus analyst Rick Wise maintained a Buy rating on
Laboratories and set a price target of $135.00, reflecting confidence in the company's future performance.Abbott's first-quarter earnings report is anticipated, with a particular focus on its Medical Devices segment. The Structural Heart,
, and Neuromodulation businesses are expected to have driven significant growth.Investors are closely watching Abbott's performance, as it accounts for approximately 18.86% of the total assets in the iShares U.S. Medical Devices ETF, highlighting its substantial influence in the medical devices sector.

Titulares diarios de acciones y criptomonedas, gratis en tu bandeja de entrada
Comentarios
Aún no hay comentarios